| Document |
Document Title |
|
WO/2023/137335A2 |
Provided are methods for treating a CD33-positive hematological malignancy, such as acute myelogenous leukemia or multiple myeloma, in a subject by administering to the subject hematopoietic stem cells (HSCs) or hematopoietic stem and pr...
|
|
WO/2023/135398A1 |
The present invention relates to a conjugate of formula (I) for medicinal use: (I), wherein Ac, the hooking head, the linking arm, the spacer, M and u are as defined in the description.
|
|
WO/2023/133645A1 |
Radiolabeled compounds that target fibroblast activation protein (FAP). The compounds have 1-6 radiolabeling groups and 1-6 FAP-targeting groups, connected by 1-11 linkers. FAP-targeting groups have the structure of Formula (I). R1a and ...
|
|
WO/2023/136712A1 |
The present invention relates to a dual-mode probe for detecting hydrogen sulfide and a use thereof and, more specifically, to a dual-mode probe that has excellent blood-brain barrier permeability and is capable of fluorescence and nucle...
|
|
WO/2023/135538A1 |
Systems, methods, and kits useful for detecting and locating internal bleeding, such as gastrointestinal bleeding, during active or inactive bleeding. In some embodiments, the systems, methods, and kits make use of a single photon emissi...
|
|
WO/2023/130587A1 |
The present invention relates to a water-soluble methylbenzene ether derivative, a positron nuclide probe and a nuclide marker, and preparation methods therefor and the uses thereof. Water-soluble side chains are introduced by means of d...
|
|
WO/2023/131800A1 |
The present disclosure relates to methods of administering [18F]-FACBC for imaging, diagnosing, and/or monitoring of myeloma bone lesions.
|
|
WO/2023/126336A1 |
The present invention relates to novel bispidine-based compounds comprising at least an optionally substituted ethanoic acid moiety at the N7-position of the bispidine scaffold, said bispidine-based compounds representing metal chelating...
|
|
WO/2023/125973A1 |
Disclosed are a nanobody for PDL1 and a use thereof. Provided are a nanobody for PDL1 and a sequence thereof. Also provided are a polynucleotide encoding the nanobody, a corresponding expression vector, a host cell capable of expressing ...
|
|
WO/2023/122753A1 |
Provided herein are compositions and methods for cross-linking single domain antibodies to targets with conjugates. Further provided herein are conjugates comprising targeting domains, wherein the targeting domain comprises an unnatural ...
|
|
WO/2023/118195A1 |
An oncological FAP-targeting pharmaceutical product has the chemical structure: FAPi—R1—FAPs—CT with R1 = formula (I) or formula (II) or formula (III), wherein FAPi stands for an FAP inhibitor, FAPs stands for an FAP substrate, CT ...
|
|
WO/2023/109377A1 |
The present invention relates to a preparation method for drug-loaded mesoporous calcium silicate modified PMMA bone cement, a product, and a use. The preparation method comprises preparation of mesoporous calcium silicate, preparation o...
|
|
WO/2023/114255A1 |
The present invention is a method and device for treating solid tumors utilizing shear thinning biomaterials compositions containing beta-or alpha emitting radiation sources, polymer matrix, and /or radiopaque agent. The novel radioactiv...
|
|
WO/2023/111176A1 |
The present invention relates to positron-emitting imaging agents for use in the prognosis of a neuroendocrine neoplasm (NEN) patient in by PET imaging of the cancer, wherein said imaging agent comprises a uPAR binding peptidecoupled via...
|
|
WO/2023/104048A1 |
The present invention relates to the field of biomedicine. Disclosed are a brain tumor-targeting polypeptide, a derivative thereof and an application thereof. Specifically disclosed is use of the polypeptide in the preparation of a brain...
|
|
WO/2023/107830A1 |
Amyloid oligomer compositions and amyloid monomer compositions used to make amyloid oligomer compositions are provided. Also provided are reagents and kits thereof that find use in preparing these compositions. These amyloid oligomer com...
|
|
WO/2023/104009A1 |
The present invention relates to a mitochondria-targeted positron emission or fluorescent probe, and a preparation method therefor and the use thereof. The probe has the structure as shown in formula (I), and is a 18F or 19F substituted ...
|
|
WO/2023/104794A1 |
The present invention relates to a linker of the present invention, a protein-payload conjugate of the present invention, payload-linker conjugate of the present invention and their respective therapeutic and diagnostic uses. The linkers...
|
|
WO/2023/104148A1 |
Disclosed are a compound shown in following general formula I, and a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1 is preferably a pyridyl group; R2 is preferably a halogen group, and halogenated C1-4 alkoxy ...
|
|
WO/2023/099472A1 |
The present invention relates to the a positron-emitting imaging agent for use in the prognosis of a head and neck cancer (HNSCC) in a subject by PET imaging of the cancer, wherein said imaging agent comprises a uPAR bindingpeptide coupl...
|
|
WO/2023/097374A1 |
Provided herein are metal-organic framework (MOF) biocomposites, in particular biocomposites comprising partially embedded biomolecules such as antibodies. Also provided herein are methods of producing the MOF biocomposites, and uses of ...
|
|
WO/2023/100852A1 |
The purpose of the present invention is to provide a stabilized radiopharmaceutical composition wherein the decrease in the radiochemical purity over time is suppressed even in the case where the radioactivity concentration is high immed...
|
|
WO/2023/097154A1 |
Provided is the use of YM155 monobromide for treating the Ewing family of tumors such as Ewing's sarcoma, and related kits, compositions, and methods, including diagnostic methods
|
|
WO/2023/092184A1 |
The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to PSMA, compositions thereof and uses thereof in methods of treatment.
|
|
WO/2023/097329A1 |
In one aspect, therapeutic use, methods of treatment and kits comprising 177Lu-PSMA I&T are provided for subjects exhibiting prostate cancer progression following administration with one or more androgen receptor inhibitor agents.
|
|
WO/2023/092830A1 |
A precursor compound of a radioactive marker as shown in formula (I), a radioactive marker thereof, or a pharmaceutically acceptable salt thereof. The radioactive marker is high in water solubility, good in in-vitro stability at room tem...
|
|
WO/2023/088134A1 |
The present disclosure provides a carborane-phospholipid conjugate, in which carboranyl is introduced at the end of the arm of a phospholipid. The present disclosure also provides a liposome composition comprising the carborane-phospholi...
|
|
WO/2023/088236A1 |
Provided are a peptide having high affinity to membrane-type matrix metalloproteinase 1 (MT1-MMP), a drug conjugate, stereoisomer, pharmaceutically acceptable salt, solvate, co-crystal or deuterated product thereof, or a pharmaceutical c...
|
|
WO/2023/091689A1 |
The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, co...
|
|
WO/2023/087734A1 |
Disclosed are a PSMA-targeting nuclide/fluorescent bimodal ligand and molecular probe, and the use thereof. The PSMA-targeting bimodal molecular probe is designed and synthesized by using dencichine-ureido as a PSMA-targeting structure, ...
|
|
WO/2023/088671A1 |
Provided is a method for the preparation of a composition comprising dissolved [18F]fluoride ions which is suitable for radiofluorination, said method comprising the steps of - providing an aqueous solution comprising water and [18F]fluo...
|
|
WO/2023/087871A1 |
The present invention belongs to the field of nuclear medicine, and relates to a granzyme B targeting complex, a radiopharmaceutical, a preparation method therefor, and a use thereof. The structure of the granzyme B targeting complex is ...
|
|
WO/2023/083998A1 |
The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alph...
|
|
WO/2023/084397A1 |
The present invention is directed to compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjug...
|
|
WO/2023/084000A1 |
The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alph...
|
|
WO/2023/083961A1 |
The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alph...
|
|
WO/2023/084445A1 |
The present invention relates to methods fortreating small cell lung cancer (SCLC), in particular small cell lung cancer (SCLC) in a subject in need thereof wherein a therapeutically efficient amount of a radiopharmaceutical compound com...
|
|
WO/2023/083209A1 |
Disclosed are a ligand compound targeting a PSMA antigen, and a chelate and the use thereof in the diagnosis and treatment of prostate cancer. The ligand compound is a compound of formula (I) or a salt, ester or solvate thereof. The pres...
|
|
WO/2023/084396A1 |
The present invention is directed to the preparation of key intermediates and synthesis of compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical c...
|
|
WO/2023/086619A1 |
A kit is provided for delivering local radiation to a tumor while also causing tumor devascularization. The kit includes a first liquid radioembolic agent for treatment of at least a first region of the tumor and a second liquid radioemb...
|
|
WO/2023/081698A1 |
Methods of treatment for conditions, e.g., cancer, using a cold IGF-1R-targeting molecule and a radioimmunoconjugate comprising a metal complex of a chelating moiety, a linker, and an IGF-1R targeting moiety.
|
|
WO/2023/081514A1 |
In various embodiments drug delivery vehicles and uses thereof are provided. In certain embodiments the drug delivery vehicles comprise: 1) a silicasome comprising a mesoporous silica nanoparticle coated with a lipid bilayer and further ...
|
|
WO/2023/081301A1 |
The present disclosure relates to Fibroblast Activating Protein( FAP) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds ...
|
|
WO/2023/073603A1 |
The present disclosure is directed to a method of treating glioblastoma in a subject in need thereof comprising administering to said subject an efficient amount of a radiopharmaceutical compound. The present disclosure is also directed ...
|
|
WO/2023/070202A1 |
Compounds, e.g., radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and an Claudin 18.2 targeting moiety. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., ...
|
|
WO/2023/073560A1 |
A nanoparticle assembly is disclosed for the treatment and visualization of cancers. The assembly includes a core and two surrounding copolymer layers. The surrounding layers include hydrogel polymers, dextran-iron oxide nanoparticles, a...
|
|
WO/2023/076220A1 |
The present disclosure provides conjugates that comprise a small molecule attached to an antifouling nanoparticle. The present disclosure also provides methods of using such conjugates, such as diagnosis, tissue imaging, temporal monitor...
|
|
WO/2022/261467A9 |
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
|
|
WO/2023/070743A1 |
A radioactive medical isotope labeled rare-earth doped nanomaterial, a PET imaging diagnosis and treatment agent, a preparation method therefor and an application thereof. The radioactive medical isotope labeled rare-earth doped nanomate...
|
|
WO/2023/068829A1 |
The present invention relates to a composition comprising iron oxide magnetic particles. The composition can be delivered specifically to hepatocytes to minimize damage to other organs, and is safe as the composition is excreted from the...
|
